Revision as of 00:27, 20 September 2022

7 regimens on this page 7 variants on this page

Adjuvant therapy

Cisplatin & Fluorouracil (CF) & Vincristine

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy
Katzenstein et al. 2019 (AHEP0731)	2010-2014	Phase 3 (E-esc)	Observation	Seems to have superior EFS

For stage 1 or 2 hepatoblastoma without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.

Preceding treatment

Curative surgical resection

Chemotherapy

Cisplatin (Platinol) by the following weight-based criteria:
- Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
- 10 kg or more: 100 mg/m² over 6 hours once on day 1
Fluorouracil by the following weight-based criteria:
- Less than 10 kg: 20 mg/kg IV once on day 2
- 10 kg or more: 600 mg/m² IV once on day 2
Vincristine by the following weight-based criteria:
- Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
- 10 kg or more: 1.5 mg/m² (maximum dose of 2 mg) IV once per day on days 2, 9, 16

21-day cycle for 1 cycle (to be given within 42 days of resection)

References

AHEP0731: Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. link to original article PubMed NCT00980460

All lines of therapy

Cisplatin monotherapy

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy	Comparative Toxicity
Perilongo et al. 2009 (SIOPEL 3)	1998-2006	Phase 3 (E-de-esc)	Cisplatin & Doxorubicin	Non-inferior complete resection rate
Brock et al. 2018 (SIOPEL 6)	2007-2014	Phase 3 (C)	Cisplatin & Sodium thiosulfate		More hearing loss

Chemotherapy

Cisplatin (Platinol)

References

SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed NCT00003912
SIOPEL 6: Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sullivan MJ, Laithier V, Ronghe M, Dall'Igna P, Hiyama E, Brichard B, Skeen J, Mateos ME, Capra M, Rangaswami AA, Ansari M, Rechnitzer C, Veal GJ, Covezzoli A, Brugières L, Perilongo G, Czauderna P, Morland B, Neuwelt EA. Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss. N Engl J Med. 2018 Jun 21;378(25):2376-2385. link to original article link to PMC article PubMed NCT00652132

Cisplatin & Doxorubicin

PLADO: PLAtinol (Cisplatin) & DOxorubicin

Regimen

Study	Years of enrollment	Evidence	Comparator	Comparative Efficacy	Comparative Toxicity
Ortega et al. 2000	1989-1992	Phase 3 (E-switch-ic)	CF & Vincristine		More toxic
Pritchard et al. 2000 (SIOPEL 1)	1990-1994	Non-randomized
Perilongo et al. 2009 (SIOPEL 3)	1998-2006	Phase 3 (C)	Cisplatin	Non-inferior complete resection rate

Chemotherapy

References

Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD; Children's Cancer Group; Pediatric Oncology Group. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. 2000 Jul;18(14):2665-75. link to original article PubMed
SIOPEL 1: Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28. link to original article PubMed
SIOPEL 3: Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. link to original article PubMed NCT00003912

@@ Line 10: / Line 10: @@
 |}
 {{TOC limit|limit=3}}
+=Adjuvant therapy=
+==Cisplatin & Fluorouracil (CF) & Vincristine {{#subobject:50f9da|Regimen=1}}==
+===Regimen===
+{| class="wikitable sortable" style="width: 100%; text-align:center;"
+!style="width: 20%"|Study
+!style="width: 20%"|Years of enrollment
+!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
+!style="width: 20%"|Comparator
+!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
+|-
+|[https://doi.org/10.1016/S1470-2045(18)30895-7 Katzenstein et al. 2019 (AHEP0731)]
+|2010-2014
+| style="background-color:#1a9851" |Phase 3 (E-esc)
+|[[#Observation|Observation]]
+| style="background-color:#91cf60" |Seems to have superior EFS
+|-
+|}
+''For stage 1 or 2 '''hepatoblastoma''' without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.''
+====Preceding treatment====
+*Curative [[Surgery#Hepatobiliary_cancer_surgery|surgical resection]]
+====Chemotherapy====
+*[[Cisplatin (Platinol)]] by the following weight-based criteria:
+**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
+**10 kg or more: 100 mg/m<sup>2</sup> over 6 hours once on day 1
+*[[Fluorouracil (5-FU)|Fluorouracil]] by the following weight-based criteria:
+**Less than 10 kg: 20 mg/kg IV once on day 2
+**10 kg or more: 600 mg/m<sup>2</sup> IV once on day 2
+*[[Vincristine (Oncovin)|Vincristine]] by the following weight-based criteria:
+**Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
+**10 kg or more: 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 2, 9, 16
+'''21-day cycle for 1 cycle (to be given within 42 days of resection)'''
+===References===
+#'''AHEP0731:''' Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. [https://doi.org/10.1016/S1470-2045(18)30895-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30975630/ PubMed] NCT00980460
 =All lines of therapy=
@@ Line 87: / Line 129: @@
 # '''SIOPEL 1:''' Pritchard J, Brown J, Shafford E, Perilongo G, Brock P, Dicks-Mireaux C, Keeling J, Phillips A, Vos A, Plaschkes J. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. 2000 Nov 15;18(22):3819-28. [https://doi.org/10.1200/jco.2000.18.22.3819 link to original article] [https://pubmed.ncbi.nlm.nih.gov/11078495 PubMed]
 # '''SIOPEL 3:''' Perilongo G, Maibach R, Shafford E, Brugieres L, Brock P, Morland B, de Camargo B, Zsiros J, Roebuck D, Zimmermann A, Aronson D, Childs M, Widing E, Laithier V, Plaschkes J, Pritchard J, Scopinaro M, MacKinlay G, Czauderna P. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. 2009 Oct 22;361(17):1662-70. [https://doi.org/10.1056/NEJMoa0810613 link to original article] [https://pubmed.ncbi.nlm.nih.gov/19846851 PubMed] NCT00003912
-==Cisplatin & Fluorouracil (CF) & Vincristine {{#subobject:50f9da|Regimen=1}}==
-===Regimen===
-{| class="wikitable sortable" style="width: 100%; text-align:center;"
-!style="width: 20%"|Study
-!style="width: 20%"|Years of enrollment
-!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
-!style="width: 20%"|Comparator
-!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]]
-|-
-|[https://doi.org/10.1016/S1470-2045(18)30895-7 Katzenstein et al. 2019 (AHEP0731)]
-|2010-2014
-| style="background-color:#1a9851" |Phase 3 (E-esc)
-|[[#Observation|Observation]]
-| style="background-color:#91cf60" |Seems to have superior EFS
-|-
-|}
-''For stage 1 or 2 '''hepatoblastoma''' without 100% pure fetal stage I or small-cell undifferentiated histology with complete resection at diagnosis and no history of prior chemotherapy or liver directed therapy. Eligible patients include: patients< 21 years old, elevated serum α-fetoprotein level (>100 ng/mL), at least 50% Karnofsky (patients >16 years) or Lansky (patients ≤16 years) performance status.''
-====Preceding treatment====
-*Curative [[Surgery#Hepatobiliary_cancer_surgery|surgical resection]]
-====Chemotherapy====
-*[[Cisplatin (Platinol)]] by the following weight-based criteria:
-**Less than 10 kg: 3.3 mg/kg IV over 6 hours once on day 1
-**10 kg or more: 100 mg/m<sup>2</sup> over 6 hours once on day 1
-*[[Fluorouracil (5-FU)|Fluorouracil]] by the following weight-based criteria:
-**Less than 10 kg: 20 mg/kg IV once on day 2
-**10 kg or more: 600 mg/m<sup>2</sup> IV once on day 2
-*[[Vincristine (Oncovin)|Vincristine]] by the following weight-based criteria:
-**Less than 10 kg: 0.05 mg/kg IV once per day on days 2, 9, 16
-**10 kg or more: 1.5 mg/m<sup>2</sup> (maximum dose of 2 mg) IV once per day on days 2, 9, 16
-'''21-day cycle for 1 cycle (to be given within 42 days of resection)'''
-===References===
-#'''AHEP0731:''' Katzenstein HM, Langham MR, Malogolowkin MH, Krailo MD, Towbin AJ, McCarville MB, Finegold MJ, Ranganathan S, Dunn S, McGahren ED, Tiao GM, O'Neill AF, Qayed M, Furman WL, Xia C, Rodriguez-Galindo C, Meyers RL; Children's Oncology Group. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis (AHEP0731): a Children's Oncology Group, multicentre, phase 3 trial. Lancet Oncology. 2019 May 1. 20(5) 719-727. Epub 2019 Apr 8. [https://doi.org/10.1016/S1470-2045(18)30895-7 link to original article] [https://pubmed.ncbi.nlm.nih.gov/30975630/ PubMed] NCT00980460
 [[Category:Hepatoblastoma regimens]]
 [[Category:Disease-specific pages]]
 [[Category:Pediatric solid tumors]]

Difference between revisions of "Hepatoblastoma"

Revision as of 00:27, 20 September 2022

Contents

Adjuvant therapy

Cisplatin & Fluorouracil (CF) & Vincristine

Regimen

Preceding treatment

Chemotherapy

References

All lines of therapy

Cisplatin monotherapy

Regimen

Chemotherapy

References

Cisplatin & Doxorubicin

Regimen

Chemotherapy

References

Navigation menu

Search